Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevaciz...
Uložené v:
| Vydané v: | The lancet oncology Ročník 18; číslo 6; s. 779 - 791 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Elsevier Ltd
01.06.2017
Elsevier Limited |
| Predmet: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here.
The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851.
Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5–62·2 for chemotherapy plus bevacizumab; IQR 40·8–59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7–46·2) versus 37·3 months (32·6–39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683–1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680–0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]).
The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients.
National Cancer Institute and Genentech. |
|---|---|
| AbstractList | Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here.
The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851.
Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5–62·2 for chemotherapy plus bevacizumab; IQR 40·8–59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7–46·2) versus 37·3 months (32·6–39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683–1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680–0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]).
The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients.
National Cancer Institute and Genentech. Summary Background Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. Methods The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov , number NCT00565851. Findings Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5–62·2 for chemotherapy plus bevacizumab; IQR 40·8–59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7–46·2) versus 37·3 months (32·6–39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683–1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680–0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). Interpretation The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. Funding National Cancer Institute and Genentech. Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851. Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5-62·2 for chemotherapy plus bevacizumab; IQR 40·8-59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7-46·2) versus 37·3 months (32·6-39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683-1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680-0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. National Cancer Institute and Genentech. Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. Methods The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged >=18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered withClinicalTrials.gov, numberNCT00565851. Findings Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5-62·2 for chemotherapy plus bevacizumab; IQR 40·8-59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7-46·2) versus 37·3 months (32·6-39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683-1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680-0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%]vstwo [1%]), fatigue (27 [8%]vseight [2%]), and proteinuria (27 [8%]vsnone). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). Interpretation The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. Funding National Cancer Institute and Genentech. Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here.BACKGROUNDPlatinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here.The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851.METHODSThe multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851.Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5-62·2 for chemotherapy plus bevacizumab; IQR 40·8-59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7-46·2) versus 37·3 months (32·6-39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683-1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680-0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]).FINDINGSBetween Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5-62·2 for chemotherapy plus bevacizumab; IQR 40·8-59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7-46·2) versus 37·3 months (32·6-39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683-1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680-0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]).The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients.INTERPRETATIONThe addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients.National Cancer Institute and Genentech.FUNDINGNational Cancer Institute and Genentech. |
| Author | Walker, Joan L Davidson, Susan A Mannel, Robert S Armstrong, Deborah K Brady, Mark F Basen-Engquist, Karen Chan, John K Kim, Byoung-Gie Fujiwara, Keiichi O'Malley, David M Spirtos, Nick M Coleman, Robert L DiSilvestro, Paul Huang, Helen Herzog, Thomas J Ashfaq, Raheela Tewari, Krishnansu S Sabbatini, Paul Rubin, Stephen C |
| Author_xml | – sequence: 1 givenname: Robert L surname: Coleman fullname: Coleman, Robert L email: rcoleman@mdanderson.org organization: Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 2 givenname: Mark F surname: Brady fullname: Brady, Mark F organization: NRG Oncology/Gynecologic Oncology Group Statistics & Data Center, University of Buffalo, Buffalo, NY, USA – sequence: 3 givenname: Thomas J surname: Herzog fullname: Herzog, Thomas J organization: Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, OH, USA – sequence: 4 givenname: Paul surname: Sabbatini fullname: Sabbatini, Paul organization: Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA – sequence: 5 givenname: Deborah K surname: Armstrong fullname: Armstrong, Deborah K organization: Departments of Obstetrics and Gynecology and Department of Medical Oncology, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA – sequence: 6 givenname: Joan L surname: Walker fullname: Walker, Joan L organization: Department of Obstetrics and Gynecology, The University of Oklahoma, Oklahoma City, OK, USA – sequence: 7 givenname: Byoung-Gie surname: Kim fullname: Kim, Byoung-Gie organization: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwayn University School of Medicine, Seoul, South Korea – sequence: 8 givenname: Keiichi surname: Fujiwara fullname: Fujiwara, Keiichi organization: Department of Obstetrics and Gynecology, Saitama Medical University International Medical Center, Hidaka-Shi, Japan – sequence: 9 givenname: Krishnansu S surname: Tewari fullname: Tewari, Krishnansu S organization: Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange, CA, USA – sequence: 10 givenname: David M surname: O'Malley fullname: O'Malley, David M organization: Department of Obstetrics and Gynecology, The Ohio State University, James Cancer Hospital, Columbus, OH, USA – sequence: 11 givenname: Susan A surname: Davidson fullname: Davidson, Susan A organization: Department of Obstetrics and Gynecology, University of Colorado School of Medicine and Denver Health Medical Center, Denver, CO, USA – sequence: 12 givenname: Stephen C surname: Rubin fullname: Rubin, Stephen C organization: Department of Obstetrics and Gynecology, Fox Chase Cancer Center, Philadelphia, PA, USA – sequence: 13 givenname: Paul surname: DiSilvestro fullname: DiSilvestro, Paul organization: Department of Obstetrics and Gynecology, Women & Infants Hospital, Providence, RI, USA – sequence: 14 givenname: Karen surname: Basen-Engquist fullname: Basen-Engquist, Karen organization: Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 15 givenname: Helen surname: Huang fullname: Huang, Helen organization: NRG Oncology/Gynecologic Oncology Group Statistics & Data Center, University of Buffalo, Buffalo, NY, USA – sequence: 16 givenname: John K surname: Chan fullname: Chan, John K organization: Gynecologic Cancer Program, California Pacific—Palo Alto Medical Foundation, Sutter Research Institute, San Francisco, CA, USA – sequence: 17 givenname: Nick M surname: Spirtos fullname: Spirtos, Nick M organization: Women's Cancer Center, Las Vegas, NV, USA – sequence: 18 givenname: Raheela surname: Ashfaq fullname: Ashfaq, Raheela organization: Miraca Life Sciences, Irving, TX, USA – sequence: 19 givenname: Robert S surname: Mannel fullname: Mannel, Robert S organization: Department of Obstetrics and Gynecology, The University of Oklahoma, Oklahoma City, OK, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28438473$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNku1qFDEUhgdR7IdeghLwTwsdm8xXZhUrWnQVigU_foczmTPd1EwyJpnF9Zf34B16BV6C2dlatSAVAnPIvOfJe5J3J7lprMEkucfoQ0ZZdfiOFZymGS3KPcb3c5rxWVrdSLbjdpGWRV3fnOqNZCvZ8f6cUsYZLW8nW1ld5HXB8-3kx3NcglRfxh4aAqYlA0itAnxG_f3rNwmusYOGoAyRC-xtWKCDYTUpPUprWnArIlfBOmxHGZQ1JGodytE5NOGAbLrHPvVovApqicQuwSmIRDASHdl783ZOTo202p6tDucrg1Op5OUmmTs7DsSHsY316TylGcv3HxEg_aiDkvEghwfEDmhSDQ3qA-KiQ9srj220sACPJCchnqrvJLc60B7vXnx3kw8vX7w_fpWenM5fHz87SWVFi5BWeVE2QHnWsaaTFcg2l3XXYNfKpm6Lqislz2kJEgBkBjMeV9eihKqoM6h4vpscbbjD2PTYTh5Bi8GpPl6ZsKDE33-MWogzuxQlZ2VRsQjYuwA4-2lEH0QcR6LWYNCOXrB6xup6VtU0Sh9ckZ7b0Zk4nmAzynNW1VkWVff_dHRp5VcYoqDcCKSz3jvsLiWMinXoxBQ6sU6UYFxMoRNV7Ht8pU_GBK2zEAdT-trup5tujK-xVOiElwpjMloVYxREa9W1hKMrhBhhoyToj7hC__suhM8E3UDWDMYnwhrw5N-A_zDwE64RIOc |
| CitedBy_id | crossref_primary_10_3390_ijms21207768 crossref_primary_10_3389_fphar_2024_1416555 crossref_primary_10_1080_14656566_2023_2295393 crossref_primary_10_1038_s41416_024_02602_0 crossref_primary_10_1016_j_bulcan_2019_04_003 crossref_primary_10_1080_14740338_2018_1532500 crossref_primary_10_1038_s41571_023_00819_1 crossref_primary_10_1186_s12957_022_02621_2 crossref_primary_10_1007_s00280_019_03917_z crossref_primary_10_1007_s10147_021_01935_7 crossref_primary_10_1038_s41591_024_02981_0 crossref_primary_10_3390_ph18060850 crossref_primary_10_1016_S1470_2045_21_00006_1 crossref_primary_10_3389_fphar_2021_726278 crossref_primary_10_1038_s41467_024_45595_3 crossref_primary_10_3390_nu14122376 crossref_primary_10_1016_j_ygyno_2021_10_008 crossref_primary_10_1038_s41416_021_01605_5 crossref_primary_10_1200_JCO_19_00337 crossref_primary_10_3390_app11093807 crossref_primary_10_1080_14740338_2018_1550067 crossref_primary_10_1097_CAD_0000000000000858 crossref_primary_10_1097_MD_0000000000036750 crossref_primary_10_1007_s12094_024_03531_3 crossref_primary_10_3390_cancers15112980 crossref_primary_10_1111_iwj_14531 crossref_primary_10_1016_j_ctrv_2025_102945 crossref_primary_10_3390_cancers14174219 crossref_primary_10_1097_COC_0000000000000999 crossref_primary_10_1186_s13048_021_00842_9 crossref_primary_10_3390_cancers13184603 crossref_primary_10_1016_j_ijgc_2025_101918 crossref_primary_10_1186_s12964_022_00838_y crossref_primary_10_1177_10781552241307868 crossref_primary_10_1158_1078_0432_CCR_21_3659 crossref_primary_10_1097_AOG_0000000000004173 crossref_primary_10_1097_AOG_0000000000003086 crossref_primary_10_1002_cncr_32475 crossref_primary_10_1038_s41598_022_07731_1 crossref_primary_10_1007_s00404_020_05865_z crossref_primary_10_3390_cancers12040965 crossref_primary_10_1007_s10637_022_01281_z crossref_primary_10_1200_JCO_19_00314 crossref_primary_10_1080_17425247_2020_1739647 crossref_primary_10_1080_17425255_2018_1461838 crossref_primary_10_1016_S1470_2045_20_30061_9 crossref_primary_10_1007_s00432_020_03168_z crossref_primary_10_1111_1471_0528_17328 crossref_primary_10_3390_ijms232012358 crossref_primary_10_3390_diagnostics13061040 crossref_primary_10_3390_jcm10194529 crossref_primary_10_1016_j_critrevonc_2022_103703 crossref_primary_10_1093_annonc_mdx228 crossref_primary_10_1200_EDBK_238755 crossref_primary_10_1007_s11912_021_01128_5 crossref_primary_10_3390_ijms21165840 crossref_primary_10_1016_j_gore_2024_101450 crossref_primary_10_3390_cancers12082239 crossref_primary_10_2147_CMAR_S531276 crossref_primary_10_1186_s12957_023_03230_3 crossref_primary_10_3389_fonc_2022_796983 crossref_primary_10_1016_j_ygyno_2018_10_020 crossref_primary_10_3390_cancers12051206 crossref_primary_10_3390_cancers17183069 crossref_primary_10_1080_14796694_2025_2513848 crossref_primary_10_1186_s13048_022_01028_7 crossref_primary_10_1055_a_2092_7893 crossref_primary_10_1016_j_ajog_2025_01_026 crossref_primary_10_1038_s41416_020_01098_8 crossref_primary_10_1016_S1470_2045_17_30253_X crossref_primary_10_3390_ijms22020843 crossref_primary_10_1002_ijc_32606 crossref_primary_10_1093_jnci_djab169 crossref_primary_10_1038_s41392_020_0199_6 crossref_primary_10_1007_s00404_022_06425_3 crossref_primary_10_3389_fonc_2024_1329133 crossref_primary_10_1016_j_drup_2025_101237 crossref_primary_10_1016_j_ygyno_2024_01_052 crossref_primary_10_3390_cancers13225783 crossref_primary_10_1136_ijgc_2018_000142 crossref_primary_10_1016_j_ygyno_2025_02_015 crossref_primary_10_3390_cancers12061676 crossref_primary_10_1200_JCO_19_00500 crossref_primary_10_1016_j_gore_2023_101186 crossref_primary_10_1080_14728214_2019_1696773 crossref_primary_10_1016_j_ygyno_2018_11_036 crossref_primary_10_1016_j_ygyno_2024_01_045 crossref_primary_10_1097_CCO_0000000000001162 crossref_primary_10_4274_ahot_galenos_2025_2025_6_5 crossref_primary_10_1016_j_imlet_2024_106864 crossref_primary_10_1016_j_bulcan_2019_11_015 crossref_primary_10_1007_s11523_020_00780_4 crossref_primary_10_5935_1806_6054_20190008 crossref_primary_10_1016_j_ctrv_2018_06_001 crossref_primary_10_1016_j_ygyno_2022_12_009 crossref_primary_10_1097_CAD_0000000000000794 crossref_primary_10_1056_NEJMoa2103294 crossref_primary_10_1016_j_bbrc_2022_01_110 crossref_primary_10_1016_j_ygyno_2018_11_028 crossref_primary_10_1093_annonc_mdx441 crossref_primary_10_1136_ijgc_2019_000308 crossref_primary_10_1016_j_semcancer_2020_08_017 crossref_primary_10_1158_1078_0432_CCR_21_2599 crossref_primary_10_1200_EDBK_199665 crossref_primary_10_1016_j_ygyno_2017_11_020 crossref_primary_10_1007_s10456_020_09734_w crossref_primary_10_1016_j_ygyno_2021_01_028 crossref_primary_10_1016_j_ijgc_2024_100010 crossref_primary_10_1016_j_ygyno_2018_05_029 crossref_primary_10_1002_cac2_12157 crossref_primary_10_1016_j_ejphar_2018_07_049 crossref_primary_10_1080_0284186X_2019_1711175 crossref_primary_10_3390_diagnostics14171852 crossref_primary_10_3390_cancers16051063 crossref_primary_10_1016_j_intimp_2024_112112 crossref_primary_10_1016_j_ygyno_2022_06_022 crossref_primary_10_1016_j_ejphar_2022_174752 crossref_primary_10_1177_0272989X211026288 crossref_primary_10_1007_s40273_020_00970_y crossref_primary_10_3389_pore_2021_1609963 crossref_primary_10_1016_j_ygyno_2017_11_026 crossref_primary_10_1056_NEJMoa1902626 crossref_primary_10_1007_s12254_018_0392_2 crossref_primary_10_1186_s13048_020_00673_0 crossref_primary_10_1007_s10637_018_0665_y crossref_primary_10_1186_s12885_022_09455_x crossref_primary_10_1111_jog_14277 crossref_primary_10_1038_s41416_019_0481_y crossref_primary_10_1158_1078_0432_CCR_19_0226 crossref_primary_10_1016_j_ygyno_2018_12_008 crossref_primary_10_1007_s10147_022_02247_0 crossref_primary_10_1038_s41417_021_00317_5 crossref_primary_10_1002_ijgo_12620 crossref_primary_10_1016_j_ygyno_2018_08_027 crossref_primary_10_56050_01205498_2373 crossref_primary_10_1158_1078_0432_CCR_20_0219 crossref_primary_10_3390_cancers16152651 crossref_primary_10_1016_j_annonc_2021_02_015 crossref_primary_10_3389_fonc_2024_1514120 crossref_primary_10_1016_j_ygyno_2018_05_001 crossref_primary_10_1093_cei_uxab020 crossref_primary_10_1016_j_critrevonc_2018_06_020 crossref_primary_10_3322_caac_21559 crossref_primary_10_1093_jjco_hyaa140 crossref_primary_10_3390_ijms24032292 crossref_primary_10_1016_j_annonc_2021_02_017 crossref_primary_10_2217_fon_2022_1273 crossref_primary_10_1007_s10147_020_01826_3 crossref_primary_10_1016_j_ctrv_2020_102017 crossref_primary_10_1080_17843286_2021_1964051 crossref_primary_10_1186_s12885_020_07658_8 crossref_primary_10_3390_molecules25153514 crossref_primary_10_1007_s00129_020_04729_6 crossref_primary_10_1200_JCO_19_01009 crossref_primary_10_3892_mco_2021_2462 crossref_primary_10_1073_pnas_1818357116 crossref_primary_10_1093_jnci_djaa061 crossref_primary_10_1245_s10434_020_09366_w crossref_primary_10_1016_j_ygyno_2021_02_032 crossref_primary_10_1097_GRF_0000000000000500 crossref_primary_10_3389_fphar_2019_00426 crossref_primary_10_3802_jgo_2026_37_e15 crossref_primary_10_1097_GCO_0000000000000931 crossref_primary_10_1159_000501618 crossref_primary_10_3390_cancers10080266 crossref_primary_10_1016_j_annonc_2023_07_011 crossref_primary_10_1097_MD_0000000000033271 crossref_primary_10_1111_jog_15673 crossref_primary_10_1158_1078_0432_CCR_23_2249 crossref_primary_10_1016_j_ygyno_2018_08_036 crossref_primary_10_3390_biom14050585 crossref_primary_10_1158_0008_5472_CAN_20_2701 crossref_primary_10_1186_s13048_019_0579_0 crossref_primary_10_1136_ijgc_2022_003993 crossref_primary_10_1200_JCO_19_01670 crossref_primary_10_3390_biomedicines10020362 crossref_primary_10_1016_j_jmig_2017_10_024 crossref_primary_10_1016_j_ctrv_2020_102107 crossref_primary_10_1016_j_tranon_2020_100860 crossref_primary_10_1111_jog_14350 crossref_primary_10_1097_JCMA_0000000000000262 crossref_primary_10_1245_s10434_022_12459_3 crossref_primary_10_1016_j_canlet_2023_216469 crossref_primary_10_1186_s13048_020_00751_3 crossref_primary_10_3802_jgo_2025_36_e36 crossref_primary_10_1200_JCO_2017_74_5752 crossref_primary_10_1016_j_clon_2018_05_008 crossref_primary_10_1007_s00404_021_06013_x crossref_primary_10_1016_j_clinthera_2025_07_012 crossref_primary_10_1016_S0140_6736_17_32440_6 crossref_primary_10_1093_nar_gkae994 crossref_primary_10_1016_j_ygyno_2020_01_042 crossref_primary_10_1016_j_ygyno_2018_07_017 crossref_primary_10_1007_s11523_023_00970_w crossref_primary_10_1016_j_annonc_2025_01_015 crossref_primary_10_1016_j_ygyno_2022_04_011 crossref_primary_10_3390_ijms21113805 crossref_primary_10_1136_ijgc_2022_003658 crossref_primary_10_1016_j_ygyno_2020_01_037 crossref_primary_10_1007_s40242_022_1325_5 crossref_primary_10_3390_cells9081896 crossref_primary_10_7759_cureus_15563 crossref_primary_10_1016_j_bbcan_2023_189036 crossref_primary_10_1016_j_soc_2019_08_008 crossref_primary_10_1016_j_bbcan_2020_188446 crossref_primary_10_1177_17588359251332471 crossref_primary_10_3390_ijms18091967 crossref_primary_10_3390_pharmaceutics17020268 crossref_primary_10_1016_j_bbadis_2025_167971 crossref_primary_10_1186_s13048_021_00816_x crossref_primary_10_3389_fphar_2023_1131342 crossref_primary_10_1016_j_soncn_2019_02_009 crossref_primary_10_3390_ijms22126532 crossref_primary_10_1007_s13346_025_01941_6 crossref_primary_10_1136_ijgc_2020_001789 crossref_primary_10_1007_s00129_022_04904_x crossref_primary_10_1177_11795549231187264 crossref_primary_10_1080_14740338_2023_2271830 crossref_primary_10_1136_ijgc_2023_004777 crossref_primary_10_1016_j_ctrv_2021_102240 crossref_primary_10_1016_j_ygyno_2020_05_039 crossref_primary_10_1007_s40944_020_00485_6 crossref_primary_10_1007_s11912_021_01163_2 crossref_primary_10_1007_s11864_020_00747_7 crossref_primary_10_1080_14779072_2019_1704626 crossref_primary_10_1002_jcb_29445 crossref_primary_10_1016_S1470_2045_20_30637_9 crossref_primary_10_3390_ph17060778 crossref_primary_10_1007_s12094_020_02446_z crossref_primary_10_1016_j_ogc_2018_09_010 crossref_primary_10_1038_s41416_022_01717_6 crossref_primary_10_1136_ijgc_2020_001407 crossref_primary_10_1016_j_ygyno_2018_06_017 crossref_primary_10_1186_s12885_018_4498_z crossref_primary_10_1007_s10330_022_0557_7 crossref_primary_10_1038_s41598_021_83685_0 crossref_primary_10_1007_s10555_023_10113_2 crossref_primary_10_3389_fphar_2023_1147717 crossref_primary_10_1097_CMR_0000000000000812 crossref_primary_10_3389_fonc_2022_960317 crossref_primary_10_1007_s10147_022_02169_x crossref_primary_10_3390_medicina58020244 crossref_primary_10_1007_s00280_018_3645_1 crossref_primary_10_1007_s40266_017_0495_1 crossref_primary_10_1136_ijgc_2020_001517 crossref_primary_10_1002_adtp_202000144 crossref_primary_10_1016_j_ogc_2018_09_005 crossref_primary_10_1016_S1470_2045_19_30515_7 crossref_primary_10_1136_bmj_m3773 crossref_primary_10_1016_j_semcancer_2023_11_007 crossref_primary_10_1007_s12094_020_02545_x crossref_primary_10_1080_14656566_2022_2112030 crossref_primary_10_1016_j_ogc_2018_09_009 crossref_primary_10_1007_s00761_018_0511_z crossref_primary_10_1038_s41698_024_00688_6 crossref_primary_10_3892_ol_2021_12462 crossref_primary_10_1016_j_critrevonc_2023_104238 crossref_primary_10_1016_j_critrevonc_2023_104230 crossref_primary_10_1038_s41467_023_40829_2 crossref_primary_10_1038_s41598_020_63634_z crossref_primary_10_1634_theoncologist_2019_0020 crossref_primary_10_1186_s13048_022_01020_1 crossref_primary_10_1186_s40661_017_0050_0 crossref_primary_10_3390_cancers16142545 crossref_primary_10_3389_fnins_2023_1187957 crossref_primary_10_1136_ijgc_2024_005700 crossref_primary_10_1016_j_ygyno_2022_07_011 crossref_primary_10_1016_j_ygyno_2021_05_018 crossref_primary_10_1038_s43018_023_00617_9 crossref_primary_10_1016_j_ygyno_2019_02_008 crossref_primary_10_1038_s41467_024_45974_w crossref_primary_10_3389_fonc_2022_830570 crossref_primary_10_1007_s40265_019_01158_1 crossref_primary_10_2217_fon_2019_0042 crossref_primary_10_1016_j_ijgc_2025_101896 crossref_primary_10_1093_jjco_hyaa071 crossref_primary_10_1016_j_ctrv_2021_102224 crossref_primary_10_1016_j_ejso_2025_110016 crossref_primary_10_1080_14737140_2017_1398088 crossref_primary_10_12688_f1000research_11771_1 crossref_primary_10_3389_fonc_2023_1114435 crossref_primary_10_1136_jitc_2023_007099 crossref_primary_10_1155_2019_7056872 crossref_primary_10_1155_2022_4880355 crossref_primary_10_1093_annonc_mdz062 crossref_primary_10_1097_MD_0000000000019931 crossref_primary_10_1158_1078_0432_CCR_18_0042 crossref_primary_10_1186_s13048_022_01055_4 crossref_primary_10_1177_17588359231173183 crossref_primary_10_1016_j_ygyno_2018_01_010 crossref_primary_10_1097_COC_0000000000001100 crossref_primary_10_3390_biomedicines13071525 crossref_primary_10_1080_1120009X_2021_1947022 crossref_primary_10_1080_14656566_2020_1775813 crossref_primary_10_1080_14740338_2022_1996561 crossref_primary_10_1016_j_ygyno_2018_01_008 crossref_primary_10_1016_j_ygyno_2023_01_020 crossref_primary_10_4103_jmedsci_jmedsci_225_24 crossref_primary_10_1016_S0007_4551_21_00584_1 crossref_primary_10_1080_14728214_2020_1773791 crossref_primary_10_1007_s00404_024_07863_x crossref_primary_10_1055_s_0042_1742321 crossref_primary_10_1111_imm_13888 crossref_primary_10_1016_j_ygyno_2019_03_246 crossref_primary_10_3390_diagnostics11040640 crossref_primary_10_1007_s00404_019_05104_0 crossref_primary_10_1001_jamanetworkopen_2020_0363 crossref_primary_10_1016_j_ygyno_2020_07_031 crossref_primary_10_1016_j_ygyno_2020_10_010 crossref_primary_10_1007_s11523_019_00665_1 crossref_primary_10_1097_GCO_0000000000000434 crossref_primary_10_1158_1541_7786_MCR_23_0015 crossref_primary_10_1001_jamanetworkopen_2023_26834 crossref_primary_10_1016_j_micres_2025_128342 crossref_primary_10_3390_cancers13133177 crossref_primary_10_1177_0300891620966382 crossref_primary_10_1016_S0140_6736_18_32552_2 crossref_primary_10_1515_hsz_2017_0274 crossref_primary_10_1177_10732748231159553 crossref_primary_10_1016_j_yao_2024_01_005 crossref_primary_10_1136_ijgc_2019_001041 crossref_primary_10_2217_fon_2017_0302 crossref_primary_10_3390_ijerph18126629 crossref_primary_10_1002_adbi_202300480 crossref_primary_10_1053_j_ackd_2021_09_003 crossref_primary_10_1016_j_cell_2024_06_013 crossref_primary_10_1016_j_prp_2023_154470 crossref_primary_10_1016_j_ygyno_2019_11_006 crossref_primary_10_1111_cas_15185 crossref_primary_10_1002_cncr_32500 crossref_primary_10_1186_s12967_020_02331_x crossref_primary_10_2147_CMAR_S249540 crossref_primary_10_1016_j_ygyno_2018_10_031 crossref_primary_10_1016_j_ygyno_2018_01_011 crossref_primary_10_1007_s11523_019_00641_9 crossref_primary_10_1016_j_hoc_2018_07_005 crossref_primary_10_1007_s12672_024_01267_8 crossref_primary_10_2217_fon_2017_0316 crossref_primary_10_1016_j_hoc_2018_07_009 crossref_primary_10_1016_S1470_2045_20_30142_X crossref_primary_10_1016_j_hoc_2018_07_008 crossref_primary_10_1038_s41568_022_00503_z crossref_primary_10_3390_ijms21145034 crossref_primary_10_3390_diagnostics13223484 crossref_primary_10_3390_ph17081095 crossref_primary_10_3389_fonc_2020_01095 crossref_primary_10_1097_CAD_0000000000001472 crossref_primary_10_1200_EDBK_25_473114 crossref_primary_10_1016_S1470_2045_21_00073_5 crossref_primary_10_1038_s41416_022_01852_0 crossref_primary_10_3390_cancers13061298 crossref_primary_10_3390_cancers15133470 crossref_primary_10_1007_s00261_019_02175_0 crossref_primary_10_1016_j_ejso_2024_107950 crossref_primary_10_3390_cells14130995 crossref_primary_10_3390_cancers14051122 crossref_primary_10_1186_s12905_023_02329_9 crossref_primary_10_3390_jcm12052065 crossref_primary_10_1016_j_ctarc_2022_100629 crossref_primary_10_3390_jcm13020566 crossref_primary_10_1177_1078155219895070 crossref_primary_10_3389_fimmu_2023_1308143 crossref_primary_10_1080_14796694_2024_2372241 crossref_primary_10_1016_j_ejphar_2023_175586 crossref_primary_10_1007_s10585_018_9889_7 crossref_primary_10_1016_j_ygyno_2024_03_006 crossref_primary_10_1016_j_bbcan_2023_188888 crossref_primary_10_1080_09205063_2021_1967701 crossref_primary_10_1097_GCO_0000000000000592 crossref_primary_10_1016_j_ygyno_2019_04_001 crossref_primary_10_1111_iwj_14737 crossref_primary_10_1172_JCI174013 crossref_primary_10_31083_j_ceog5109208 crossref_primary_10_1016_j_ygyno_2023_01_003 crossref_primary_10_1245_s10434_020_08812_z crossref_primary_10_1007_s00761_025_01765_6 crossref_primary_10_1200_JCO_2017_77_0446 crossref_primary_10_3389_fonc_2024_1414112 crossref_primary_10_1007_s00280_021_04323_0 crossref_primary_10_3389_fonc_2022_843278 crossref_primary_10_1007_s00404_021_06282_6 crossref_primary_10_1007_s00280_024_04659_3 crossref_primary_10_1016_j_ygyno_2020_04_694 crossref_primary_10_1002_cncr_32544 crossref_primary_10_1093_annonc_mdz104 crossref_primary_10_3390_cancers15102869 crossref_primary_10_1016_S1470_2045_22_00139_5 crossref_primary_10_1186_s12935_021_02295_y crossref_primary_10_5858_arpa_2023_0149_OA |
| Cites_doi | 10.1200/JCO.2013.51.4489 10.1200/JCO.2015.65.8153 10.1200/JCO.2009.25.7519 10.1016/j.ygyno.2015.07.008 10.1016/S0923-7534(20)31480-0 10.1016/S1470-2045(15)00366-6 10.1093/jnci/92.3.205 10.1038/nature14410 10.1111/j.2517-6161.1972.tb00899.x 10.1016/j.ygyno.2009.03.018 10.1056/NEJMoa1103799 10.1056/NEJMoa1104390 10.1517/14728214.2015.1036739 10.1016/S0140-6736(15)01167-8 10.1200/JCO.2015.63.1408 10.1200/JCO.2012.42.0505 10.1002/(SICI)1097-0142(19961115)78:10<2049::AID-CNCR4>3.0.CO;2-J 10.1200/JCO.2014.55.7348 10.1097/IGC.0b013e318290ea69 10.2307/2531701 10.1111/IGC.0b013e3181c104fa 10.1016/j.ygyno.2016.05.017 10.1016/S1470-2045(14)70244-X 10.1016/j.ygyno.2014.09.017 10.1038/nrclinonc.2013.5 10.1200/JCO.2001.19.6.1809 10.1093/clinchem/42.11.1777 10.1002/cncr.24149 10.1200/JCO.2006.06.0913 10.1200/JCO.2006.07.3494 10.1158/1078-0432.CCR-04-1148 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Ltd Elsevier Ltd Copyright © 2017 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jun 1, 2017 |
| Copyright_xml | – notice: 2017 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2017 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jun 1, 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1016/S1470-2045(17)30279-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 791 |
| ExternalDocumentID | PMC5715461 28438473 10_1016_S1470_2045_17_30279_6 S1470204517302796 1_s2_0_S1470204517302796 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Journal Article |
| GrantInformation | National Cancer Institute and Genentech. |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U10 CA180868 – fundername: NCI NIH HHS grantid: UG1 CA189867 – fundername: NCI NIH HHS grantid: U10 CA027469 – fundername: NCATS NIH HHS grantid: UL1 TR001414 – fundername: NCI NIH HHS grantid: U10 CA180850 – fundername: NCI NIH HHS grantid: U10 CA037517 – fundername: NCI NIH HHS grantid: UG1 CA233196 – fundername: NCI NIH HHS grantid: U10 CA180822 – fundername: NCI NIH HHS grantid: U10 CA180858 – fundername: NCI NIH HHS grantid: U10 CA180802 |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c604t-6345ba072f1bfc6acd3c8fbefdcb8d46f5c7305acaaac2a97a97fdeca6482a673 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 491 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000402805700052&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Tue Nov 04 02:03:59 EST 2025 Mon Sep 29 05:34:18 EDT 2025 Mon Oct 06 18:37:11 EDT 2025 Wed Feb 19 02:27:52 EST 2025 Sat Nov 29 07:01:01 EST 2025 Tue Nov 18 21:42:06 EST 2025 Fri Feb 23 02:31:14 EST 2024 Tue Feb 25 20:02:55 EST 2025 Tue Oct 14 19:39:00 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Copyright © 2017 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c604t-6345ba072f1bfc6acd3c8fbefdcb8d46f5c7305acaaac2a97a97fdeca6482a673 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://doi.org/10.1016/S1470-2045(17)30279-6 |
| PMID | 28438473 |
| PQID | 1907316822 |
| PQPubID | 46089 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5715461 proquest_miscellaneous_1891889680 proquest_journals_1907316822 pubmed_primary_28438473 crossref_primary_10_1016_S1470_2045_17_30279_6 crossref_citationtrail_10_1016_S1470_2045_17_30279_6 elsevier_sciencedirect_doi_10_1016_S1470_2045_17_30279_6 elsevier_clinicalkeyesjournals_1_s2_0_S1470204517302796 elsevier_clinicalkey_doi_10_1016_S1470_2045_17_30279_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-01 |
| PublicationDateYYYYMMDD | 2017-06-01 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Cox (bib22) 1972; 34 Patch, Christie, Etemadmoghadam (bib2) 2015; 521 Coleman, Monk, Sood (bib1) 2013; 10 Poveda, Selle, Hilpert (bib24) 2015; 33 Perren, Swart, Pfisterer (bib11) 2011; 365 Ueda M, Hung YC, Terai Y, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Pfisterer, Plante, Vergote (bib33) 2006; 24 Monk, Sill, Walker (bib31) 2016; 34 Backes, Richardson, McCann (bib32) 2013; 23 Schlaeppi, Eppenberger, Martiny-Baron (bib4) 1996; 42 (bib19) 2006 Chi, Eisenhauer, Zivanovic (bib26) 2009; 114 Basen-Engquist, Bodurka-Bevers, Fitzgerald (bib18) 2001; 19 Ledermann, Embleton, Raja (bib8) 2016; 387 Monk, Coleman (bib3) 2009; 19 Therasse, Arbuck, Eisenhauer (bib16) 2000; 92 Graybill, Sood, Monk (bib7) 2015; 138 Jackson, Eisenhauer, Herzog (bib6) 2015; 20 du Bois, Floquet, Kim (bib15) 2014; 32 Bristow, Lagasse, Karlan (bib27) 1996; 78 Lee, Lord, Grunewald (bib29) 2015; 136 Rustin, Nelstrop, Bentzen (bib17) 1999; 10 Petrillo, Amadio, Salutari (bib30) 2016; 142 Pujade-Lauraine, Hilpert, Weber (bib9) 2014; 32 du Bois, Reuss, Pujade-Lauraine (bib25) 2009; 115 Lan, DeMets (bib20) 1989; 45 Pujade-Lauraine, Wagner, Aavall-Lundqvist (bib28) 2010; 28 Aghajanian, Blank, Goff (bib10) 2012; 30 du Bois, Kristensen, Ray-Coquard (bib13) 2016; 17 3225–32. Wenzel, Huang, Armstrong (bib23) 2007; 25 Monk, Poveda, Vergote (bib14) 2014; 15 Mantel (bib21) 1966; 50 Burger, Brady, Bookman (bib12) 2011; 365 Pujade-Lauraine (10.1016/S1470-2045(17)30279-6_bib9) 2014; 32 Schlaeppi (10.1016/S1470-2045(17)30279-6_bib4) 1996; 42 Poveda (10.1016/S1470-2045(17)30279-6_bib24) 2015; 33 Patch (10.1016/S1470-2045(17)30279-6_bib2) 2015; 521 Perren (10.1016/S1470-2045(17)30279-6_bib11) 2011; 365 Wenzel (10.1016/S1470-2045(17)30279-6_bib23) 2007; 25 Lan (10.1016/S1470-2045(17)30279-6_bib20) 1989; 45 Petrillo (10.1016/S1470-2045(17)30279-6_bib30) 2016; 142 Basen-Engquist (10.1016/S1470-2045(17)30279-6_bib18) 2001; 19 Lee (10.1016/S1470-2045(17)30279-6_bib29) 2015; 136 du Bois (10.1016/S1470-2045(17)30279-6_bib13) 2016; 17 Coleman (10.1016/S1470-2045(17)30279-6_bib1) 2013; 10 du Bois (10.1016/S1470-2045(17)30279-6_bib25) 2009; 115 Pfisterer (10.1016/S1470-2045(17)30279-6_bib33) 2006; 24 10.1016/S1470-2045(17)30279-6_bib5 Monk (10.1016/S1470-2045(17)30279-6_bib3) 2009; 19 Aghajanian (10.1016/S1470-2045(17)30279-6_bib10) 2012; 30 Backes (10.1016/S1470-2045(17)30279-6_bib32) 2013; 23 Pujade-Lauraine (10.1016/S1470-2045(17)30279-6_bib28) 2010; 28 Therasse (10.1016/S1470-2045(17)30279-6_bib16) 2000; 92 Graybill (10.1016/S1470-2045(17)30279-6_bib7) 2015; 138 Burger (10.1016/S1470-2045(17)30279-6_bib12) 2011; 365 Monk (10.1016/S1470-2045(17)30279-6_bib14) 2014; 15 Cox (10.1016/S1470-2045(17)30279-6_bib22) 1972; 34 Chi (10.1016/S1470-2045(17)30279-6_bib26) 2009; 114 (10.1016/S1470-2045(17)30279-6_bib19) 2006 Rustin (10.1016/S1470-2045(17)30279-6_bib17) 1999; 10 Ledermann (10.1016/S1470-2045(17)30279-6_bib8) 2016; 387 Monk (10.1016/S1470-2045(17)30279-6_bib31) 2016; 34 Bristow (10.1016/S1470-2045(17)30279-6_bib27) 1996; 78 du Bois (10.1016/S1470-2045(17)30279-6_bib15) 2014; 32 Mantel (10.1016/S1470-2045(17)30279-6_bib21) 1966; 50 Jackson (10.1016/S1470-2045(17)30279-6_bib6) 2015; 20 28438475 - Lancet Oncol. 2017 Jun;18(6):701-702 |
| References_xml | – reference: 3225–32. – volume: 387 start-page: 1066 year: 2016 end-page: 1074 ident: bib8 article-title: Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet – volume: 33 start-page: 3836 year: 2015 end-page: 3838 ident: bib24 article-title: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial publication-title: J Clin Oncol – volume: 115 start-page: 1234 year: 2009 end-page: 1244 ident: bib25 article-title: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) publication-title: Cancer – volume: 142 start-page: 231 year: 2016 end-page: 236 ident: bib30 article-title: Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: a case-control study publication-title: Gynecol Oncol – volume: 25 start-page: 437 year: 2007 end-page: 443 ident: bib23 article-title: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study publication-title: J Clin Oncol – volume: 34 start-page: 2279 year: 2016 end-page: 2286 ident: bib31 article-title: Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG Oncology/Gynecologic Oncology Group Study publication-title: J Clin Oncol – volume: 30 start-page: 2039 year: 2012 end-page: 2045 ident: bib10 article-title: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer publication-title: J Clin Oncol – volume: 138 start-page: 223 year: 2015 end-page: 226 ident: bib7 article-title: State of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancer publication-title: Gynecol Oncol – volume: 32 start-page: 1302 year: 2014 end-page: 1308 ident: bib9 article-title: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial publication-title: J Clin Oncol – year: 2006 ident: bib19 publication-title: Common Terminology Criteria for Adverse Events v3.0 (CTCAE) – volume: 17 start-page: 78 year: 2016 end-page: 89 ident: bib13 article-title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet Oncol – volume: 50 start-page: 163 year: 1966 end-page: 170 ident: bib21 article-title: Evaluation of survival data and two new rank order statistics arising in its consideration publication-title: Cancer Chem Rep – volume: 19 start-page: S63 year: 2009 end-page: S67 ident: bib3 article-title: Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds publication-title: Int J Gynecol Cancer – volume: 42 start-page: 1777 year: 1996 end-page: 1784 ident: bib4 article-title: Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates publication-title: Clin Chem – volume: 92 start-page: 205 year: 2000 end-page: 216 ident: bib16 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst – volume: 365 start-page: 2484 year: 2011 end-page: 2496 ident: bib11 article-title: A phase 3 trial of bevacizumab in ovarian cancer publication-title: N Engl J Med – volume: 32 start-page: 3374 year: 2014 end-page: 3382 ident: bib15 article-title: Incorporation of pazopanib in maintenance therapy of ovarian cancer publication-title: J Clin Oncol – volume: 136 start-page: 18 year: 2015 end-page: 24 ident: bib29 article-title: Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial publication-title: Gynecol Oncol – volume: 365 start-page: 2473 year: 2011 end-page: 2483 ident: bib12 article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer publication-title: N Engl J Med – volume: 521 start-page: 489 year: 2015 end-page: 494 ident: bib2 article-title: Whole-genome characterization of chemoresistant ovarian cancer publication-title: Nature – volume: 23 start-page: 833 year: 2013 end-page: 838 ident: bib32 article-title: Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? publication-title: Int J Gynecol Cancer – volume: 114 start-page: 26 year: 2009 end-page: 31 ident: bib26 article-title: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm publication-title: Gynecol Oncol – volume: 20 start-page: 331 year: 2015 end-page: 346 ident: bib6 article-title: Emerging therapies: angiogenesis inhibitors for ovarian cancer publication-title: Expert Opin Emerg Drugs – volume: 10 start-page: 211 year: 2013 end-page: 224 ident: bib1 article-title: Latest research and treatment of advanced-stage epithelial ovarian cancer publication-title: Nature Rev Clin Oncol – volume: 24 start-page: 4699 year: 2006 end-page: 4707 ident: bib33 article-title: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG publication-title: J Clin Oncol – volume: 45 start-page: 1017 year: 1989 end-page: 1020 ident: bib20 article-title: Changing frequency of interim analysis in sequential monitoring publication-title: Biometrics – volume: 78 start-page: 2049 year: 1996 end-page: 2062 ident: bib27 article-title: Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature publication-title: Cancer – volume: 34 start-page: 187 year: 1972 end-page: 220 ident: bib22 article-title: Regression models and life tables publication-title: J Royal Statist Soc – volume: 28 start-page: 3323 year: 2010 end-page: 3329 ident: bib28 article-title: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse publication-title: J Clin Oncol – volume: 10 start-page: 21 year: 1999 end-page: 27 ident: bib17 article-title: Use of tumour markers in monitoring the course of ovarian cancer publication-title: Ann Oncol – volume: 19 start-page: 1809 year: 2001 end-page: 1817 ident: bib18 article-title: Reliability and validity of the functional assessment of cancer therapy-ovarian publication-title: J Clin Oncol – volume: 15 start-page: 799 year: 2014 end-page: 808 ident: bib14 article-title: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial publication-title: Lancet Oncol – reference: Ueda M, Hung YC, Terai Y, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. – volume: 32 start-page: 1302 year: 2014 ident: 10.1016/S1470-2045(17)30279-6_bib9 article-title: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2013.51.4489 – volume: 34 start-page: 2279 year: 2016 ident: 10.1016/S1470-2045(17)30279-6_bib31 article-title: Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG Oncology/Gynecologic Oncology Group Study publication-title: J Clin Oncol doi: 10.1200/JCO.2015.65.8153 – volume: 28 start-page: 3323 year: 2010 ident: 10.1016/S1470-2045(17)30279-6_bib28 article-title: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse publication-title: J Clin Oncol doi: 10.1200/JCO.2009.25.7519 – volume: 138 start-page: 223 year: 2015 ident: 10.1016/S1470-2045(17)30279-6_bib7 article-title: State of the science: emerging therapeutic strategies for targeting angiogenesis in ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2015.07.008 – volume: 10 start-page: 21 issue: suppl 1 year: 1999 ident: 10.1016/S1470-2045(17)30279-6_bib17 article-title: Use of tumour markers in monitoring the course of ovarian cancer publication-title: Ann Oncol doi: 10.1016/S0923-7534(20)31480-0 – volume: 17 start-page: 78 year: 2016 ident: 10.1016/S1470-2045(17)30279-6_bib13 article-title: Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00366-6 – year: 2006 ident: 10.1016/S1470-2045(17)30279-6_bib19 – volume: 92 start-page: 205 year: 2000 ident: 10.1016/S1470-2045(17)30279-6_bib16 article-title: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.3.205 – volume: 521 start-page: 489 year: 2015 ident: 10.1016/S1470-2045(17)30279-6_bib2 article-title: Whole-genome characterization of chemoresistant ovarian cancer publication-title: Nature doi: 10.1038/nature14410 – volume: 50 start-page: 163 year: 1966 ident: 10.1016/S1470-2045(17)30279-6_bib21 article-title: Evaluation of survival data and two new rank order statistics arising in its consideration publication-title: Cancer Chem Rep – volume: 34 start-page: 187 year: 1972 ident: 10.1016/S1470-2045(17)30279-6_bib22 article-title: Regression models and life tables publication-title: J Royal Statist Soc doi: 10.1111/j.2517-6161.1972.tb00899.x – volume: 114 start-page: 26 year: 2009 ident: 10.1016/S1470-2045(17)30279-6_bib26 article-title: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2009.03.018 – volume: 365 start-page: 2484 year: 2011 ident: 10.1016/S1470-2045(17)30279-6_bib11 article-title: A phase 3 trial of bevacizumab in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1103799 – volume: 365 start-page: 2473 year: 2011 ident: 10.1016/S1470-2045(17)30279-6_bib12 article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1104390 – volume: 20 start-page: 331 year: 2015 ident: 10.1016/S1470-2045(17)30279-6_bib6 article-title: Emerging therapies: angiogenesis inhibitors for ovarian cancer publication-title: Expert Opin Emerg Drugs doi: 10.1517/14728214.2015.1036739 – volume: 387 start-page: 1066 year: 2016 ident: 10.1016/S1470-2045(17)30279-6_bib8 article-title: Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)01167-8 – volume: 33 start-page: 3836 year: 2015 ident: 10.1016/S1470-2045(17)30279-6_bib24 article-title: Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial publication-title: J Clin Oncol doi: 10.1200/JCO.2015.63.1408 – volume: 30 start-page: 2039 year: 2012 ident: 10.1016/S1470-2045(17)30279-6_bib10 article-title: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.0505 – volume: 78 start-page: 2049 year: 1996 ident: 10.1016/S1470-2045(17)30279-6_bib27 article-title: Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19961115)78:10<2049::AID-CNCR4>3.0.CO;2-J – volume: 32 start-page: 3374 year: 2014 ident: 10.1016/S1470-2045(17)30279-6_bib15 article-title: Incorporation of pazopanib in maintenance therapy of ovarian cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2014.55.7348 – volume: 23 start-page: 833 year: 2013 ident: 10.1016/S1470-2045(17)30279-6_bib32 article-title: Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e318290ea69 – volume: 45 start-page: 1017 year: 1989 ident: 10.1016/S1470-2045(17)30279-6_bib20 article-title: Changing frequency of interim analysis in sequential monitoring publication-title: Biometrics doi: 10.2307/2531701 – volume: 19 start-page: S63 issue: suppl 2 year: 2009 ident: 10.1016/S1470-2045(17)30279-6_bib3 article-title: Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds publication-title: Int J Gynecol Cancer doi: 10.1111/IGC.0b013e3181c104fa – volume: 142 start-page: 231 year: 2016 ident: 10.1016/S1470-2045(17)30279-6_bib30 article-title: Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: a case-control study publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2016.05.017 – volume: 15 start-page: 799 year: 2014 ident: 10.1016/S1470-2045(17)30279-6_bib14 article-title: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70244-X – volume: 136 start-page: 18 year: 2015 ident: 10.1016/S1470-2045(17)30279-6_bib29 article-title: Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2014.09.017 – volume: 10 start-page: 211 year: 2013 ident: 10.1016/S1470-2045(17)30279-6_bib1 article-title: Latest research and treatment of advanced-stage epithelial ovarian cancer publication-title: Nature Rev Clin Oncol doi: 10.1038/nrclinonc.2013.5 – volume: 19 start-page: 1809 year: 2001 ident: 10.1016/S1470-2045(17)30279-6_bib18 article-title: Reliability and validity of the functional assessment of cancer therapy-ovarian publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.6.1809 – volume: 42 start-page: 1777 year: 1996 ident: 10.1016/S1470-2045(17)30279-6_bib4 article-title: Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates publication-title: Clin Chem doi: 10.1093/clinchem/42.11.1777 – volume: 115 start-page: 1234 year: 2009 ident: 10.1016/S1470-2045(17)30279-6_bib25 publication-title: Cancer doi: 10.1002/cncr.24149 – volume: 24 start-page: 4699 year: 2006 ident: 10.1016/S1470-2045(17)30279-6_bib33 article-title: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.0913 – volume: 25 start-page: 437 year: 2007 ident: 10.1016/S1470-2045(17)30279-6_bib23 article-title: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.3494 – ident: 10.1016/S1470-2045(17)30279-6_bib5 doi: 10.1158/1078-0432.CCR-04-1148 – reference: 28438475 - Lancet Oncol. 2017 Jun;18(6):701-702 |
| SSID | ssj0017105 |
| Score | 2.6733847 |
| Snippet | Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this... Summary Background Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 779 |
| SubjectTerms | Adult Aged Aged, 80 and over Angiogenesis Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - administration & dosage Bevacizumab - adverse effects Cancer therapies Carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Carcinoma, Ovarian Epithelial Chemotherapy Clinical trials Cytoreduction Surgical Procedures Disease-Free Survival Fallopian tube Fallopian Tube Neoplasms - therapy Fatigue Female Genital cancers Gynecological cancer Hematology, Oncology and Palliative Medicine Humans Immunotherapy Malignancy Middle Aged Monoclonal antibodies Motivation Myelodysplastic syndrome Neoplasm Recurrence, Local - therapy Neoplasms, Glandular and Epithelial - therapy Neutropenia Oncology Ovarian cancer Ovarian Neoplasms - therapy Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Patients Peritoneal Neoplasms - therapy Peritoneum Platinum Proteinuria Sensitivity analysis Studies Surgery Survival Survival Rate Targeted cancer therapy Toxicity Young Adult |
| Title | Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204517302796 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204517302796 https://dx.doi.org/10.1016/S1470-2045(17)30279-6 https://www.ncbi.nlm.nih.gov/pubmed/28438473 https://www.proquest.com/docview/1907316822 https://www.proquest.com/docview/1891889680 https://pubmed.ncbi.nlm.nih.gov/PMC5715461 |
| Volume | 18 |
| WOSCitedRecordID | wos000402805700052&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZgQ4gX7pfCmIzEwybVa662wwti01Ze6KZyUd8ix3a0Sm1Smrai_Gh-A-c4aca4DYkXPyQ-iZN8OXefQ8hLoZIoA2CwWEUhGChCsyTPA2Y9ZZNIG-CWyjWbEIOBHI2Ss8bhVjVplRue6Bi1KTX6yHsguFyTpSB4PfvMsGsURlebFhrXybaPshvwLIaf2iiCqFMY_Uh4DMuuX-zg6b1vD-75Yh-Ddwnjf5JNv-qeP6dQ_iCTTu7879PcJbcbbZS-qeFzj1yzxX1y810Tb39Avh3aldLjr8upyqgqDAULG6t6f7ETptU8K2eYSldQ-PLTZivX2s2r0M42ar6meg1WPdaHRQRQmDtHDz_WhOrSmno5ZRWm0SPjpeUKjHcFV0Q0zuneYNinp4Urrb3u9deF1TW3bg9S5z2jrkwu7Z_2GagT4f4rqqjLlXRvznYpdgljgHg76VIQz6YEfFsDSzgHMU5D6rqXPCQfT44_HL1lTYcIprkXLRgPozhTnghyP8s1V9qEWuaZzY3OpIl4HmvgYLHSSikdqASQKXJjteKRDBQX4SOyVZSFfUJobD1uUH8TWkci8TIOilvsKS7DUGQm6ZBog41UN-XTsYvHJG3z5BBSKUIq9UXqIJXyDjloyWZ1_ZCrCPgGeOlmcyyw8xQk3FWE4neEtmqYUpX6aRWkXk2NxL5wpEApW8pG76r1qX-56c4G3-nFfVpwd8iL9jR8VoxFqcKWS5gjE1_KhEuvQx7Xv1L7fkBjCkFpCuGJLv1k7QQsiX75TDE-d6XRYwEmAfef_n1Zz8itALUz50zbIVuL-dI-Jzf0ajGu5ruOh-A4Em6UMMojf5dsHx4PzobfAYA3fn4 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwELZKQcAL97FQwEggtVJNc9oJEkJc3VZttxUUqW_GcRy10m6yJLuF5Ufx0_gNzDhHKVd56QOvib8c9hyf7fEMIY-EioMEBIOFKvBhgiI0i7PMY8ZRJg50CtZS2WITYjCI9vbinTnytT0Lg2GVrU20hjotNK6Rr4DjskWWPO_5-CPDqlG4u9qW0KjFYsPMPsGUrXq2_hrG97Hnrb7ZfbXGmqoCTHMnmDDuB2GiHOFlbpJprnTq6yhLTJbqJEoDnoUapD5UWimlPRXD34gsNVrxIPIUFz489ww5C3ZcYAiZ2OsmeK6oQybdQDgM07wfnRhaedddXHTFEm4Wxoz_yRf-ynV_Dtn8wQeuXv7feu8KudSwbfqiVo-rZM7k18j5rSae4Dr59tIcKn3wZTpSCVV5SsdKY9byz2bItCqTYoyhgjkFyR41R9Vmtl2F6wipKmdUzyZFiflvUcIptC1xBwNzXi3TGj0dsQqPCaBjocWhApWHJ6K2lXRx8LZPt3ObOny20p_lRtfeqLtI7eogtWmAaX-7z4Au-UtPqaI2FtSOlFmmWAWNgUab4TIF-pEWoL8mhU_YB5pCfWqrs9wg70-lt2-S-bzIzW1CQ-PwFPmp0DoQsZNwIKaho3jk-yJJ4x4JWlmUukkPj1VKhrKLA0QRlijC0hXSirDkPfKkg43r_CgnAXgr6LI9_AvuSoIHPwkofgc0VWN0K-nKypNOjUawKywUkFGHbHhlzRf_5aULrT7Jo_d0ytQjD7vbMKy416ZyU0yhTRS7URTzyOmRW7Xqdv0DjNAHUujDHx1T6q4Bpnw_fic_2Lep30MBUx7u3vn7Zz0gF9Z2tzbl5vpg4y656CETtQuHC2R-Uk7NPXJOH04OqvK-tV-UfDhtlf8OC0zcRA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwELZKQRUv3MdCASOB1Eo1m9NOkBACSpeqsK0KSH0zjuOoK22TJdktLD-NH8VvYMY5SrnKSx94TTw57PlmPtvjGUIeCBUHCSgGC1XgwwRFaBZnmceMo0wc6BSspbLFJsRwGO3txTsL5Gt7FgbDKlubaA11WmhcI--D47JFljyvnzVhETvrG08nHxlWkMKd1racRq0iW2b-CaZv1ZPNdRjrh5638fLdi1esqTDANHeCKeN-ECbKEV7mJpnmSqe-jrLEZKlOojTgWagBAaHSSintqRj-TGSp0YoHkae48OG5Z8hZ4fsCy0aIvW6y54o6fNINhMMw5fvR6aH-2-7iiitWceMwZvxPfvFX3vtz-OYP_nDj4v_ck5fIhYaF02c1bC6TBZNfIUtvmjiDq-Tbc3Oo9OjL7EAlVOUpnSiN2cw_mzHTqkyKCYYQ5hQ0_qA5wja37SpcX0hVOad6Pi1KzIuLmk-hbYk7G5gLa43W0rMDVuHxAXQ4tDhUYArgiYjCkq4Mdwd0O7cpxef9wTw3uvZS3UVqVw2pTQ9MB9sDBjTKX31MFbUxonbUzBrF6mgMkG7GaxRoSVoArk0Kn7AP9IX61FZtuUben0pvXyeLeZGbm4SGxuEp8lahdSBiJ-FAWENH8QiUOknjHglavZS6SRuP1UvGsosPRHWWqM7SFdKqs-Q98qgTm9R5U04S4K3Sy_ZQMLgxCZ79JEHxO0FTNca4kq6sPOnU0ijsCisKklEn2fDNmkf-y0uXW2zJo_d0wOqR-91tGFbcg1O5KWbQJordKIp55PTIjRrGXf8AU_SBLPrwR8cA3jXAVPDH7-SjfZsSPhQwFeLurb9_1j2yBEiXrzeHW7fJeQ8Jql1PXCaL03Jm7pBz-nA6qsq71pRR8uG0Ef8dXSbk-A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bevacizumab+and+paclitaxel%E2%80%93carboplatin+chemotherapy+and+secondary+cytoreduction+in+recurrent%2C+platinum-sensitive+ovarian+cancer+%28NRG+Oncology%2FGynecologic+Oncology+Group+study+GOG-0213%29%3A+a+multicentre%2C+open-label%2C+randomised%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Coleman%2C+Robert+L&rft.au=Brady%2C+Mark+F&rft.au=Herzog%2C+Thomas+J&rft.au=Sabbatini%2C+Paul&rft.date=2017-06-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.volume=18&rft.issue=6&rft.spage=779&rft.epage=791&rft_id=info:doi/10.1016%2FS1470-2045%2817%2930279-6&rft.externalDocID=S1470204517302796 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon |